Precision Medicine for L/GCMN and Melanoma 1 (Precis-mel 2)
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Genetic, Device
Study Type: Observational
SUMMARY
The primary objective is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for the early identification of metastases. The secondary objective is to evaluate the usability of these technologies in the follow up of high-risk melanoma patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Be over 18 years old
• Have a histopathological confirmed melanoma diagnosis (stage II, III or IV AJCC)
Locations
Other Locations
Spain
Hospital Clínic Barcelona
RECRUITING
Barcelona
Hospital Clínic Barcelona
RECRUITING
Barcelona
Hospital Clínic de Barcelona (Dermatology service)
NOT_YET_RECRUITING
Barcelona
Contact Information
Primary
Susana Puig Sardà, PhD, MD
spuig@clinic.cat
+34932275400
Backup
Adrián López Canosa, PhD
lopez64@recerca.clinic.cat
Time Frame
Start Date: 2025-01-01
Estimated Completion Date: 2026-12-01
Participants
Target number of participants: 100
Treatments
Melanoma (non-metastatic)
Patients of either sex over 18 years old with histopathological confirmed melanoma in a non metastatic stage (I to IIb stages according to AJCC classification)
Melanoma (metastatic)
Patients of either sex over 18 years old with histopathological confirmed melanoma in a metastatic stage (IIIa to IV stages according to AJCC classification)
Related Therapeutic Areas
Sponsors
Collaborators: Hospital Clinic of Barcelona
Leads: Fundacion Clinic per a la Recerca Biomédica